The performance of the stock price over the year has been up and down, leaving investors with either an optimistic or pessimistic outlook, depending on how they interpret the data. The index has shown a price gain of 146.20% this year. Over the last six months, there has been a weaker performance of 129.22%. The price of AUPH leaped by -3.92% during the last 30 days period. For the last 5-days stocks have slided -0.69%.
The present stock price for Aurinia Pharmaceuticals Inc. (AUPH) is $10.64. In the last trading session, the stock made a considerable jump, reaching $11.575 after an opening price of $11.20. The stock briefly fell to $11.13 before ending the session at $11.31.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
The market performance of Aurinia Pharmaceuticals Inc.’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $13.41 on 06/08/22, while the lowest value for the same duration was $4.07 on 12/28/22.
52-week price history of AUPH Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Aurinia Pharmaceuticals Inc.’s current trading price is -20.72% away from its 52-week high, while its distance from the 52-week low is 161.33%. The stock’s price range during this period has varied between$4.07 and $13.41. The Aurinia Pharmaceuticals Inc.’s shares, which operate in the Healthcare, saw a trading volume of around 1.88 million for the day, a figure considerably lower than their average daily volume of 3.1 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Aurinia Pharmaceuticals Inc. (AUPH) has experienced a quarterly rise of 26.62% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 1.63B and boasts a workforce of 300 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 9.54, with a change in price of +6.19. Similarly, Aurinia Pharmaceuticals Inc. recorded 3,247,769 in trading volume during the last 100 days, posting a change of +141.53%.
AUPH’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for AUPH stands at 0.00. Similarly, the long-term debt-to-equity ratio is also 0.00.
AUPH Stock Stochastic Average
Aurinia Pharmaceuticals Inc.’s raw stochastic average for the past 50 days is presently 54.16%, as of today. This marks a increase from the raw stochastic average of the last 20 days, which was 25.42%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 48.85% and 46.74%, respectively.
